Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer

Roche today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq ® (atezolizumab) and Cotellic® (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib. The study evaluated the combination in people with difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) whose disease progressed or who were intole rant to at least two systemic chemotherapy regimens.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news